CardioBites: SGLT2is

CardioBites: Understanding The Burden of Heart Failure

The 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America Guideline for the Management of Heart Failure includes 4 classes of medication for guideline-directed medical therapy. Guidance for sodium-glucose cotransporter-2 inhibitors (SGLT2is) is now included for some patients. Learn more about the burden of heart failure, and how the guidelines recommend incorporating these therapies to improve our patients’ quality of life in the CardioBites Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) series.

SGLT2i Videos in the Series

CardioBites: SGLT2is: Understanding the Burden of Heart Failure
Heart failure affects some 6.7 million Americans over 20 years of age. This number is expected to grow to 8.5 million in the next 6 years. In this module, we explore the burden heart failure places on morbidity, mortality, and hospitalization.
Watch now

Current Guidelines on the Use of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Heart Failure
Sodium-glucose cotransporter-2 inhibitors (SGLT2is), were originally intended as a diabetes medication, but have also been helpful in treatment heart failure. Learn more about SGLT2i therapy, and it can help your patients with this condition.
Watch now

The impact of Hospital Readmissions on Quality of Life in Heart Failure
Hospital readmission for heart failure increases costs and the risks of morbidity and mortality. In this video, we examine how readmissions negatively impact the patient's health-related quality of life.
Watch now

Improving the Transition of Care in Heart Failure
How a patient transitions from one level of care to another can affect their outcomes and enhance their quality of life. In this video, we explore how we can facilitate the transfer of care and help address our patients' specific needs as they move from one level of care to another.
Watch now

Why Guideline-Directed Medical Therapy in Heart Failure Matters
Current guidelines for heart failure with reduced ejection fraction recommend the initiation and optimization of guideline-directed medical therapy to improve patient outcomes. In this video, we review why GDMT in heart failure matters.
Watch now

Understanding the Burden of Heart Failure Infographic
View now

Subscribe to the HFSA YouTube Channel

Subscribe to the HFSA YouTube channel.

Supporter(s)

The Heart Failure Society of America acknowledges Lexicon Pharmaceuticals, Inc. for providing an independent grant to support the HFSA CardioBites: SGLT2is.

Summary

Cost:

FREE

Credit:

No Credit Offered

Create Account